Exclusive Transduction of Human CD4+ T Cells upon Systemic Delivery of CD4-Targeted Lentiviral Vectors

Abstract

Playing a central role in both innate and adaptive immunity, CD4+ T cells are a key target for genetic modifications in basic research and immunotherapy. In this article, we describe novel lentiviral vectors (CD4-LV) that have been rendered selective for human or simian CD4+ cells by surface engineering. When applied to PBMCs, CD4-LV transduced CD4+ but not CD4− cells. Notably, also unstimulated T cells were stably genetically modified. Upon systemic or intrasplenic administration into mice reconstituted with human PBMCs or hematopoietic stem cells, reporter gene expression was predominantly detected in lymphoid organs. Evaluation of GFP expression in organ-derived cells and blood by flow cytometry demonstrated exclusive gene transfer into CD4+ human lymphocytes. In bone marrow and spleen, memory T cells were preferentially hit. Toward therapeutic applications, we also show that CD4-LV can be used for HIV gene therapy, as well as for tumor therapy, by delivering chimeric Ag receptors. The potential for in vivo delivery of the FOXP3 gene was also demonstrated, making CD4-LV a powerful tool for inducible regulatory T cell generation. In summary, our work demonstrates the exclusive gene transfer into a T cell subset upon systemic vector administration opening an avenue toward novel strategies in immunotherapy.

Pseudotyped Lentiviral Vectors: One Vector, Many Guises

“…85 A similar approach used a CD4-binding Designed Ankyrin Repeat Protein (DARPin) linked to MV-H protein to target LVs to CD4+ T cells. 86 An even more targeted and perhaps universal approach relies on using antibodies to specific surface proteins to provide targeting. Successful cell targeting has been achieved using a modified Sindbis virus m168 envelope.…”

Expression of Herpes Simplex Virus Thymidine Kinase/Ganciclovir by RNA Trans-Splicing Induces Selective Killing of HIV-Producing Cells

“…), and lentiviral-mediated gene transfer of bone-marrow cells has been demonstrated to be feasible in patients,77, 78, 79 which could be a potential delivery method for RNA trans -splicing technology in HIV-infected individuals. Recently, Zhou et al 80 . described the generation of an engineered lentiviral vector that can selectively transduce memory CD4 + T cells.…”

Cell and gene therapy strategies to eradicate HIV reservoirs

“…As with many gene therapy strategies, efficient delivery of these enzymes to the appropriate target cells remains a challenge, though progress is being made. For instance, a group recently engineered a measles virus hemagglutinin to target CD4 [80]. Lentivirus pseudotyped with this molecule could genetically modify 2% of resting CD4+ cells in vivo.…”